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Background: Evidence for decreasing chloroquine (CQ) efficacy against Plasmodium vivax has been reported from
many endemic countries in the world. In Ethiopia, P. vivax accounts for 40% of all malaria cases and CQ is the first-line
drug for vivax malaria. Mutations in multidrug resistance 1 (pvmdr-1) and K10 insertion in the pvcrt-o genes have been
identified as possible molecular markers of CQ-resistance (CQR) in P. vivax. Despite reports of CQ treatment failures, no
data are currently available on the prevalence of molecular markers of P. vivax resistance in Ethiopia. The objective of
this study was to determine the prevalence of mutations in the pvmdr-1 and K10 insertion in the pvcrt-o genes.
Methods: A total of 36 P. vivax clinical isolates were collected from West Arsi district in Ethiopia. Sequencing was used
to analyse polymorphisms of the pvcrt-o and pvmdr-1 genes.
Results: Sequencing results of the pvmdr-1 fragment showed the presence of two non-synonymous mutations at positions
976 and 1076. The Y→ F change at codon 976 (TAC→ TTC) was observed in 21 (75%) of 28 the isolates while the F→ L
change (at codon 1076), which was due to a single mutation (TTT→ CTT), was observed in 100% of the isolates. Of 33
samples successfully amplified for the pvcrt-o, the majority of the isolates (93.9%) were wild type, without K10 insertion.
Conclusions: High prevalence of mutations in candidate genes conferring CQR in P. vivax was identified. The fact that
CQ is still the first-line treatment for vivax malaria, the significance of mutations in the pvcrt-o and pvmdr-1 genes and
the clinical response of the patients’ to CQ treatment and whether thus an association exists between point mutations
of the candidate genes and CQR requires further research in Ethiopia.
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Of the five Plasmodium species infecting humans, Plas-
modium vivax is the most widely distributed species and
the cause of 25-40% of malaria cases worldwide [1], and
substantial morbidity associated with vivax malaria has
been reported [2-4]. Despite the public health import-
ance, P. vivax malaria has received little attention and
limited funds for research and control, since it usually
produces less severe symptoms than falciparum malaria
[2,5,6]. Current treatment for vivax malaria relies pri-
marily upon two anti-malarial drugs, chloroquine (CQ)
and primaquine (PQ), with the latter being the only ef-
fective drug against the hypnozoite stage. Indeed, the
emergence of drug resistance in P. vivax particularly to* Correspondence: lgolassa@gmail.com
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mant liver stage is alarming and of high priority for
research [7-10]. It is worth noting that inadequate sur-
veillance tools delayed the detection and containment of
CQ-resistant P. falciparum resulting in increased mor-
bidity and mortality. If a repetition is to be avoided, the
threat of emerging CQ-resistant P. vivax needs to be
acknowledged quickly and widely and substantial re-
sources need to be allocated to validate and standardize
tools necessary for characterization of drug-resistant P.
vivax [10]. In Indonesia, East Timor and Papua New
Guinea, CQ-resistant vivax malaria has already reached
an alarming prevalence [11]. Furthermore, P. vivax CQR
has occurred in at least three Latin American countries
(Guyana, Peru and Brazil) [12]. The four clinical trials car-
ried out in Asia (Thailand and Pakistan) and Africa
(Ethiopia), for instance, showed that CQ alone (25 mg/kg
over 3 days) is less effective against P. vivax asexual blood. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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with PQ (15 mg of PQ base/day for 14 days) over 28 days
of follow-up [9]. To unveil the current knowledge regard-
ing the molecular mechanisms of P. vivax resistance to
CQ and the prospects for developing and standardizing
reliable molecular markers of drug resistance, Goncalves
et al. [13] reviewed the available data by combining pub-
lished in vivo and in vitro studies.
Unlike in P. falciparum, the molecular mechanism of P.
vivax CQR remains elusive [7]. This is because, previous
studies focusing on genes known to be main determinants
of CQR in P. falciparum have failed to demonstrate a
strong correlation between pvcrt-o and pvmdr-1 genotypes
and the CQR phenotype in P. vivax. Melo et al. [14], on
the other hand, showed the association of expression levels
of pvcrt-o and pvmdr-1 with CQR and severe P. vivax mal-
aria, because parasites from patients with CQR presented
up to 6.1-fold and 2.4-fold increase in pvcrt-o and pvmdr-1
expression levels, respectively, compared to the susceptible
group in the Brazilian Amazon.
Drug resistance in P. vivax is becoming more wide-
spread, hindering management of clinical cases and posing
a huge threat to the health of millions of people exposed
to the risk of vivax malaria. Analysis of the single nucleo-
tide polymorphisms (SNPs) in drug resistant genes has
proved to be useful and important in monitoring drug re-
sistance in malaria endemic countries [15]. Mutations in
multidrug resistance 1 (pvmdr-1) and K10 insertion in the
pvcrt-o genes have been identified as possible molecular
markers of CQR in P. vivax [16,17]. Few data are available
on the possible relationship between the pvcrt-o and
pvmdr-1 genes and CQR [18]. Nevertheless, there are a
number of contradicting reports regarding the association
between pvcrt-o and pvmdr-1 polymorphisms and CQR.
Some reports suggest the Y976F mutation in pvmdr-1 to
be associated with an increase in CQ IC50 value of P. vivax
isolates in vitro [19]. Non-synonymous amino acid muta-
tions in codons Y976F and F1076L of the pvmdr-1 have
been reported to have correlation with CQR although
much work remains to link these mutations irrefutably
with CQR [16,18,20]. The role of Y976F mutation in
pvmdr-1 gene suggested reduced susceptibility to CQ
[20]. Recent experiments have shown that the expression
of pvcrt-o in transgenic lines of P. falciparum modulates
CQ response [17]. A study by Fernandez-Becerra et al.
[21] demonstrated up to 21-fold and up to three-fold in-
creases in transcript levels of pvcrt-o and pvmdr-1, re-
spectively, in severe vivax malaria cases compared to
isolates from non-severe vivax malaria patients. Another
study in India showed the predominance of the wild-type
pvmdr-1 and pvcrt-o alleles [22] although one isolate had
the Y976F mutation in the pvmdr-1 gene, which could
suggest the beginning of a trend towards decreased CQ
sensitivity. In Thailand and Indonesia, where CQR iscommon, the pvmdr-1 (Y976F and F1076L) polymor-
phisms were also identified in P. vivax samples [16]. In
Latin America, where P. vivax CQR remains relatively un-
common, the Y976F and F1076L polymorphisms are rela-
tively infrequent [23,24].
Presently, Ethiopia maintains a species-specific treatment
policy: CQ without PQ is the first-line treatment for P.
vivax and artemether-lumefantrine (AL) for P. falciparum.
Unlike in many malaria endemic countries in Africa, both
P. falciparum and P. vivax substantially contribute to mal-
aria morbidity in Ethiopia in relative proportions of 60 and
40%, respectively [25,26]. In 1996, Ethiopia published its
first report of CQR, with 2% (5/255) of study patients on
CQ with persistent parasitaemia on day 7 [27] although
13% of treatment failures and subsequent reports CQR
have been documented [28-30]. Indeed, data on the pres-
ence and prevalence of mutations in pvmdr-1 and pvcrt-o
genes are limited in Ethiopia. The study was, therefore, ini-
tiated to determine the SNPs in the pvmdr-1 and pvcrt-o
genes.
Methods
Study area, samples collection and diagnosis
The samples for this study were collected from West Arsi
district from November to December 2012. Malaria trans-
mission is seasonal and unstable in this area. Study partici-
pants were patients seeking malaria diagnosis at the Aje
Health Centre, located at 0382146.3 E, 071734.2 N and
1,852 m above sea level. Malaria diagnosis was confirmed
by microscopy of Giemsa-stained blood films and the spe-
cies of Plasmodium were recorded. Finger-prick blood
samples were collected from patients and used for thick
and thin blood film preparation. Slides were considered
negative after examination of 100 high-power fields. Pa-
tients showing positive results for P. vivax infection were
treated with CQ. Blood samples spotted on filter paper
were used for molecular analyses.
Amplification and determination of pvmdr-1 and pvcrt-o
polymorphisms
DNA was extracted from blood spots on filter paper using
Chelex extraction methods as described elsewhere [31].
The pvcrt-o (K10 insertion) and pvmdr-1 (Y976F and
F1076L) genes were amplified by nested PCR using gene-
specific primers (Table 1). The outer and nested PCR con-
ditions for pvmdr-1 was as follows: 94°C, 2 min; 33 cycles
of 94°C, 15 sec; 56°C, 30 sec; 72°C, 1 min; 72°C, 7 min.
The outer PCR condition was performed in 94°C, 2 min;
30 cycles of 94°C, 15 sec; 52°C, 30 sec; 72°C, 1 min; 72°C,
7 min, while the nested PCR was performed under the fol-
lowing conditions: 94°C, 2 min; 30 cycles of 94°C, 15 sec;
57°C, 30 sec; 72°C, 1 min; 72°C, 7 min. In both the pvmdr-
1 and pvcrt-o loci, the nested forward as well as the re-
verse sequencing primer were used. PCR amplicons were
Table 1 Primers used for amplifications of pvcrt-o and
pvmdr-1 marker genes
Primers Sequences 5′ → 3′ Size (bp)









OF (Outer forward), OR (outer reverse), NF (nested forward), NR (nested reverse).
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Genome Center. Sequencing reactions were run with AB
BigDye Terminator v3.1 and spin-column based clean-up.
Sequencing samples were separated by capillary electro-
phoresis on the ABI3730XL DNA Analyzer (Applied
Biosystems).
Ethical approval
Study protocol was reviewed and approved by Institu-
tional Review Boards of Aklilu Lemma Institute of
Pathobiology, Addis Ababa University and of the
Armauer Hansen Research Institute as well as the Na-
tional Research Ethics Review Committee.
Data analysis
Since this study was a preliminary exploratory study, a
power calculation of sample size was not done. Data
were entered, validated and analysed in Microsoft Excel
2010. Allele proportions were calculated for codons of
interest by dividing the number of samples with a par-
ticular allele to the number of samples with an identifi-
able allele at that position.
Results
The pvmdr-1 gene was successfully amplified and sequenced
in 78% (28/36) of the P. vivax isolates. Two pvmdr-1 mutant
alleles were identified: Y976F alone and Y976F-F1076L. The






Wild-type (without K10 insertion)(Table 2). All (100%) isolates carried the pvmdr-1 F1076L
mutation.
The pvcrt-o gene was successfully sequenced in 92%
(33/36) of the isolates. Of the 33 samples successfully
amplified for the pvcrt-o, the majority of the samples
(93.9%) were wild type, without K10 insertion (Table 2).
Synonymous mutations or insertions (in introns) were
found in 6.1% (2/33) of the isolates.
Discussion
CQ continues to be used for the treatment of P. vivax
infection in Ethiopia despite reports of CQR from vari-
ous studies in the country [28-30,32]. It is, therefore, im-
portant to investigate the prevalence of drug-resistance
associated markers in P. vivax clinical isolates in this
country. In P. falciparum, mutations in the pfcrt and
pfmdr-1 genes have been linked to CQR but in P. vivax
the picture is still unclear regarding the possible rela-
tionship between the pvcrt-o and pvmdr-1 genes and
CQR. However, the Y976F substitution in the pvmdr-1
gene is thought to be involved in CQR in P. vivax [19]
because the geometric mean 50% inhibitory concentra-
tion of CQ was shown to be significantly higher in P.
vivax isolates carrying the Y976F mutation than in iso-
lates with the wild-type allele. On the other hand, the
ubiquitous presence of Y976F in all patients presenting
to a clinic in Papua, where CQ resistance P. vivax is
both at high and prevalent, precluded correlation with
ex vivo drug susceptibility to CQ [10]. In the Thai iso-
lates, the Y976F substitution was associated with a 1.7-
fold higher IC50 to CQ [10]. Unlike the Y976F mutation,
Suwanarusk et al. [20] found the pvmdr-1 F1076L muta-
tion in all the isolates (wild type and mutants).
In the present study, 75% of the P. vivax isolates had
the Y976F mutation in pvmdr-1. Sequencing results of
the pvmdr-1 fragment showed the presence of two non-
synonymous mutations at positions 976 and 1076. The
Y→ F change at codon 976 (TAC→ TTC) was observed
in 26 (75%) of 28 isolates. The second F→ L change (at
codon 1076), which was due to a single mutation
(TTT→CTT), was observed in 100% of isolates.
Whether isolates carrying the pvmdr-1 Y976F mutation
responded to CQ treatments differently from those iso-
lates with the wild-type sequence necessitates further
in vivo therapeutic efficacy study in Ethiopia, but reportses in pvcrt-o gene
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[19]. The difference in the prevalence of pvmdr-1 Y976F in
areas where CQR P. vivax prevails versus CQ remain effica-
cious may indicate the correlation between CQR and se-
quence polymorphisms in pvmdr-1. In Papua Indonesia,
where CQR P. vivax is present at high prevalence (>65%)
and high level [19], the pvmdr-1 Y976F mutation was
present in all patients presenting to a clinic. In contrast, the
sequence polymorphism in pvmdr-1 conferring Y976F was
identified in only 25% of Thai isolates from an area where
CQ remains efficacious. Ninety-six percent of Indonesian
isolates (where clinical resistance to CQ prevails) had Y976F
mutation, compared to 25% of Thai isolates where CQ sen-
sitivity was almost uniform [19]. The fact that that all para-
sites with the Y976F substitution in Ethiopia also carried the
F1076L mutation, as originally described by Brega et al. [22]
the F1076L mutation could be a background mutation that
precedes the Y976F substitution and could potentially pro-
vide an early warning on emerging CQR.
In Ethiopia, CQR P. vivax has been reported from vari-
ous studies. Given the high prevalence of the Y976F muta-
tions in pvmdr-1 in Southeast Asia where CQR prevails
[19], the high prevalence of pvmdr-1 Y976F mutations
identified in this study may be associated with the CQ
treatment failure reported in Ethiopia. But the exact role
of this mutation needs to be determined by a combination
of in vitro and clinical observation studies in this country.
The fact that all isolates carried the pvmdr-1 F1076L mu-
tation, substitution in this codon may be less involved in
the modulation of P. vivax susceptibility to CQ than the
pvmdr-1 Y976F mutation given that CQ is still effective
and widely used in Ethiopia. Indeed, the presence of
pvmdr-1 F1076L mutation in all susceptible and mutant
isolates challenged the role of pvmdr-1 polymorphisms in
modulating CQ responses in P. vivax [33]. On the other
hand, pvmdr-1 polymorphisms have been recently sug-
gested to be associated with CQR in Southeast Asia [19]
unlike polymorphisms in pvcrt-o that have not been asso-
ciated with CQR in P. vivax. The limitation of this study
was that it did not determine drug resistance phenotype
(either in vivo or in vitro) for the isolates undergoing mo-
lecular characterization at the pvmdr-1 and pvcrt-o genes.
Indeed, withdrawal of a given drug is recommended when
10% of infections are not responding to treatment, al-
though in practice, governments of poor countries leave it
longer [34]. The fact that CQ treatment failure reported
earlier in Ethiopia did not exceed the level to withdrawal
CQ, periodic assessment of the current status of CQR P.
vivax has great public health significance.
Conclusion
Despite the fact that P. vivax accounts for about 40% of
malaria cases, little attention has been given to the urgent
public health need to detect and to closely monitor theprogression of CQ-resistant vivax malaria in the country.
This study has observed a high prevalence of the pvmdr-1
976 F allele, which is believed to be associated with CQR in
P. vivax. In view of reports from elsewhere, the high preva-
lence of pvmdr-1 Y976F mutation identified in this study
may be associated with the reported CQ treatment failure
Ethiopia. However, determination of the exact role of this
particular mutation in P. vivax CQ responses, as well as the
roles of other identified pvmdr-1 and pvcrt-o gene muta-
tions needs further research, involving a combination of
in vitro and clinical observation studies in this country.
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